Surufatinib
- Generic Name
- Surufatinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H28N6O3S
- CAS Number
- 1308672-74-3
- Unique Ingredient Identifier
- B2K5L1L8S9
- Background
Surufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).
- Indication
单药用于治疗无法手术切除的局部晚期或转移性、进展期非功能性、分化良好（G1、G2）的胰腺和非胰腺来源的神经内分泌瘤（pNETs）。
- Associated Conditions
- -
- Associated Therapies
- -
Surufatinib in G3 Neuroendocrine Tumors
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 32
- Registration Number
- NCT05973968
The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT05839275
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT05832892
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Huihua Xiong
- Target Recruit Count
- 45
- Registration Number
- NCT05746728
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Bai-Rong Xia
- Target Recruit Count
- 37
- Registration Number
- NCT05652283
- Locations
- 🇨🇳
Anhui Cancer Hospital, Hefei, Anhui, China
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2022-11-25
- Target Recruit Count
- 60
- Registration Number
- NCT05627427
- Locations
- 🇨🇳
Rui Liu, Tianjin, Tianjin, China
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05595889
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2022-10-21
- Target Recruit Count
- 148
- Registration Number
- NCT05590572
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2022-09-06
- Lead Sponsor
- Wuhan Union Hospital, China
- Target Recruit Count
- 36
- Registration Number
- NCT05527821
- Locations
- 🇨🇳
Union hospital, Wuhan, Hubei, China
Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 60
- Registration Number
- NCT05509699
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.